{"id":523958,"date":"2021-08-05T07:33:44","date_gmt":"2021-08-05T11:33:44","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-reports-second-quarter-2021-financial-results-and-provides-corporate-update\/"},"modified":"2021-08-05T07:33:44","modified_gmt":"2021-08-05T11:33:44","slug":"strongbridge-biopharma-plc-reports-second-quarter-2021-financial-results-and-provides-corporate-update","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/strongbridge-biopharma-plc-reports-second-quarter-2021-financial-results-and-provides-corporate-update\/","title":{"rendered":"Strongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Update"},"content":{"rendered":"
\n

\n ~ Reports KEVEYIS<\/em>
\n \u00ae<\/sup>
\n \u00a0(dichlorphenamide) Second Quarter 2021 Revenue of\u00a0$10.0 Million, a 28 Percent Increase Compared to\u00a0$7.8 Million\u00a0of Revenue During Second Quarter of 2020 ~<\/em>
\n \n <\/p>\n

\n ~ Strongbridge Remains On-Track to Meet, or Potentially Exceed, the Top End of Full-Year 2021 <\/em>
\n KEVEYIS\u00a0<\/em>
\n Revenue Guidance of $34 Million to $36 Million ~<\/em>\n <\/p>\n

\n ~ RECORLEV<\/em>
\n \u00ae<\/sup>
\n (levoketoconazole)\u00a0New Drug Application (NDA) Under Review by U.S. Food & Drug Administration\u00a0(FDA) with Prescription Drug User Fee Act (PDUFA) Target Action Date of <\/em>
\n
\n January 1, 2022 ~<\/em>\n <\/p>\n

\n ~ Xeris Pharmaceuticals, Inc.\u2019s Proposed Acquisition of Strongbridge Proceeds on Schedule with Expected Closing in Early Fourth Quarter 2021 ~ <\/em>\n <\/p>\n

DUBLIN, Ireland and TREVOSE, Pa., Aug. 05, 2021 (GLOBE NEWSWIRE) — Strongbridge Biopharma plc, (Nasdaq: SBBP) (\u201cStrongbridge\u201d or the \u201cCompany\u201d), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today reported financial results for the second quarter of 2021 and provided a corporate update.<\/p>\n

\u201cStrongbridge had an exceptional second quarter, with KEVEYIS\u00ae<\/sup> (dichlorphenamide) delivering the highest net revenue for a quarter since its launch by the Company in 2017. Given our strong first half performance, we expect to meet, or potentially exceed, the higher end of our full-year 2021 KEVEYIS revenue guidance of\u00a0$34 million\u00a0to\u00a0$36 million,\u201d said John H. Johnson, chief executive officer of Strongbridge Biopharma. \u201cAdditionally, against the backdrop of the recent announcement of the proposed acquisition of Strongbridge by Xeris, we remain focused on delivering strong revenue growth for KEVEYIS, on the continued review of RECORLEV\u00ae<\/sup>\u00a0(levoketoconazole) by the FDA, and on flawlessly executing the myriad of RECORLEV pre-launch activities. Strongbridge and Xeris are working closely on all of the required steps toward the expected close of the transaction early in the fourth quarter of this year. Upon transaction close, we look forward to unlocking the value of our combined assets and providing shareholders with the opportunity to participate in the success of the Company.\u201d<\/p>\n

\n Corporate & Financial Highlights<\/strong>\n <\/p>\n

\n
\n Rare Neuromuscular Franchise: KEVEYIS<\/em>
\n <\/strong>
\n
\n
\n \u00ae<\/em>
\n <\/strong>
\n <\/sup>
\n
\n \u00a0(dichlorphenamide)<\/em>
\n <\/strong>\n <\/p>\n